Objectives This systematic review and meta-analysis aimed to assess and compare acute adverse reactions (AAR) rates among non-ionic low-osmolar contrast media (LOCM), examining administration routes and severity-specific impact on AAR rates. Materials and methods A PubMed and Cochrane Library search identified studies published between January 1989 and March 2024. Inclusion criteria focused on studies with > 100 adult patients who received intra-arterial or intravenous LOCM (iobitridol, iohexol, iomeprol, iopamidol, iopromide, and ioversol). Duplicate reports and studies with insufficient information were excluded. Data extraction and quality assessment followed PRISMA guidelines and the Newcastle Ottawa Scale. Statistical analyses were performed using R software, including random effects, meta-regression, and sub-group analysis. Results After excluding duplicates and non-compliant studies, 32 peer-reviewed articles of initially 6701 identified studies, were included in the final analysis. The pooled overall AAR rate was 0.73%, with ioversol showing the lowest rate (0.34%). From all studies, pooled rates (random effects model) of moderate and severe AARs were 0.10% and 0.014% (p < 0.01), with the lowest rates for iohexol (0.05% and 0.008%, respectively). The highest overall, moderate, and severe AAR rates were seen with iomeprol (1.38%, 0.27%, and 0.040%, respectively). LOCM type (p < 0.0001), study design (p = 0.0001), and injection route (p = 0.034) significantly influenced the overall AAR rate. In contrast, the study center number (p = 0.698), the country where the study was performed (p = 0.808), and the type of reaction (hypersensitivity vs hypersensitivity plus physiological reactions; p = 0.178) did not. Conclusion AAR rates were low but indicated significant differences between LOCM; iohexol and ioversol demonstrated the overall most favorable safety profiles. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> Knowledge about AAR is crucial for patient safety, but comprehensive data on the safety profiles of non-ionic LOCM is lacking. <Emphasis Type="BoldItalic">Findings</Emphasis> Ioversol showed the lowest overall AAR rate; iohexol demonstrated the lowest moderate/severe AAR. Study design, LOCM type, and injection route influenced AAR rates. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> This meta-analysis provides evidence for differences in non-ionic LOCM safety profiles, particularly for moderate and severe AARs. These can guide clinicians in selecting contrast agents, aiming to further reduce risks, and improve patient safety in diagnostic imaging.

Estimating the rate of acute adverse reactions to non-ionic low-osmolar contrast media: a systematic review and meta-analysis

期刊论文
出版模式：

开放获取
发表日期：

2025年4月11日

查看全文

Yuguo Wei,
Xinchao Jiang,
Mark Hibberd,
Alexis Sampedro,
Jeannette Rautenbach

摘要

Objectives

This systematic review and meta-analysis aimed to assess and compare acute adverse reactions (AAR) rates among non-ionic low-osmolar contrast media (LOCM), examining administration routes and severity-specific impact on AAR rates.

Materials and methods

A PubMed and Cochrane Library search identified studies published between January 1989 and March 2024. Inclusion criteria focused on studies with > 100 adult patients who received intra-arterial or intravenous LOCM (iobitridol, iohexol, iomeprol, iopamidol, iopromide, and ioversol). Duplicate reports and studies with insufficient information were excluded. Data extraction and quality assessment followed PRISMA guidelines and the Newcastle Ottawa Scale. Statistical analyses were performed using R software, including random effects, meta-regression, and sub-group analysis.

Results

After excluding duplicates and non-compliant studies, 32 peer-reviewed articles of initially 6701 identified studies, were included in the final analysis. The pooled overall AAR rate was 0.73%, with ioversol showing the lowest rate (0.34%). From all studies, pooled rates (random effects model) of moderate and severe AARs were 0.10% and 0.014% (p < 0.01), with the lowest rates for iohexol (0.05% and 0.008%, respectively). The highest overall, moderate, and severe AAR rates were seen with iomeprol (1.38%, 0.27%, and 0.040%, respectively). LOCM type (p < 0.0001), study design (p = 0.0001), and injection route (p = 0.034) significantly influenced the overall AAR rate. In contrast, the study center number (p = 0.698), the country where the study was performed (p = 0.808), and the type of reaction (hypersensitivity vs hypersensitivity plus physiological reactions; p = 0.178) did not.

Conclusion

AAR rates were low but indicated significant differences between LOCM; iohexol and ioversol demonstrated the overall most favorable safety profiles.

Key Points

Question Knowledge about AAR is crucial for patient safety, but comprehensive data on the safety profiles of non-ionic LOCM is lacking.

Findings Ioversol showed the lowest overall AAR rate; iohexol demonstrated the lowest moderate/severe AAR. Study design, LOCM type, and injection route influenced AAR rates.

Clinical relevance This meta-analysis provides evidence for differences in non-ionic LOCM safety profiles, particularly for moderate and severe AARs. These can guide clinicians in selecting contrast agents, aiming to further reduce risks, and improve patient safety in diagnostic imaging.